Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States

Transfusion and Apheresis Science

Volumn 51, Issue 1, 2014, Pages 17-24

  Huisman, Eline L ^a   de Silva, Shamika U ^a   de Peuter, Maria A ^a  

^a MAPI GROUP   (Netherlands)

Author keywords

Cost effectiveness analysis; Fresh frozen plasma; OctaplasTM; Transfusion; United States

Indexed keywords

FRESH FROZEN PLASMA; OCTAPLAS; DETERGENT; SOLVENT;

ALLERGIC REACTION; ARTICLE; BACTERIAL INFECTION; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; FEMALE; HEALTH CARE COST; HEPATITIS A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERMETHOD COMPARISON; LIFESPAN; LIVER FAILURE; MALE; PLASMA TRANSFUSION; QUALITY ADJUSTED LIFE YEAR; TRANSFUSION RELATED ACUTE LUNG INJURY; UNITED STATES; ADULT; BLOOD COMPONENT THERAPY; COMPARATIVE STUDY; COST; ECONOMICS; MIDDLE AGED; PLASMA; STATISTICAL MODEL;

ADULT; BLOOD COMPONENT TRANSFUSION; COSTS AND COST ANALYSIS; DETERGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PLASMA; SOLVENTS; UNITED STATES;

EID: 84930041646     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2014.07.006     Document Type: Article

References (53)

1. Yim R. Frozen plasma for transfusion: a review http://www.hospitals.unitedbloodservices.org/hospitalnewsletters/2008_09_sep_10.pdf.
2. Solheim B.G., Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006, 35(1):83-90.
3. Boucher B.A., Hannon T.J. Blood management: a primer for clinicians. Pharmacotherapy 2007, 27(10):1394-1411.
4. O'Shaughnessy D.F., Atterbury C., Bolton M.P., Murphy M., Thomas D., Yates S., et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004, 126(1):11-28.
5. Centers for Disease Control and Prevention West nile virus transmission via organ transplantation and blood transfusion - Louisiana, 2008 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5845a3.htm.
6. Pandey S., Vyas G.N. Adverse effects of plasma transfusion.
7. Octapharma OctaplasLG http://www.octaplasus.com/uploads/octaplas_approval_01-18-13.pdf.
8. Council of Europe Guide to the preparation, use and quality assurance of blood components. Recommendation No R (95) 15 on the preparation, use and quality assurance of blood components 2008, Council of Europe Press, Strasbourg. 14th ed.
9. Food and Drug Administration - Department of Health and Human Services FDA approval letter octaplas - January 17, 2013 http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/UCM336157.pdf.
10. Huisman E.L., Van Eerd M.C., Ouwens J.N., De Peuter M.A. Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG(R)) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci 2013.
11. ) versus Fresh Frozen Plasma (FFP) in critically ill patients in the UK. Transfus Apher Sci 2010, 43(3):251-259.
12. Division of Vital Statistics United States life tables, 2008 http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_03.pdf.
13. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996, 276(15):1253-1258.
14. Merck Manual 2010-2013 http://www.merckmanuals.com/professional/index.html.
15. Bureau of Labor Statistics http://data.bls.gov/cgi-bin/dsrv?cu.
16. Department of Health & Human Services USA The 2011 National Blood Collection and Utilization Survey Report http://www.hhs.gov/ash/bloodsafety/2011-nbcus.pdf.
17. Owens D.K. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998, 13(10):716-717.
18. Hirth R.A., Chernew M.E., Miller E., Fendrick A.M., Weissert W.G. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000, 20(3):332-342.
19. Department of Health & Human Services USA The 2009 National Blood Collection and Utilization Survey http://www.aabb.org/research/hemovigilance/nbcus/Documents/09-nbcus-report.pdf.
20. Eder A.F., Herron R.M., Strupp A., Dy B., White J., Notari E.P., et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010, 50(8):1732-1742.
21. Eder A.F., Herron R., Strupp A., Dy B., Notari E.P., Chambers L.A., et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007, 47(4):599-607.
22. Tabor E., Epstein J.S. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002, 42(9):1230-1237.
23. Stramer S.L. Impact of NAT on serological screening of transfusion-transmitted agents. ISBT Sci Ser 2006, 1(1):194-202.
24. Dodd R.Y., Notari E.P., Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor-ápopulation. Transfusion 2002, 42(8):975-979.
25. Dodd R.Y. Emerging infections, transfusion safety, and epidemiology. N Engl J Med 2003, 349(13):1205-1206.
26. Wasley A., Kruszon-Moran D., Kuhnert W., Simard E.P., Finelli L., McQuillan G., et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010, 202(2):192-201.
27. Cohen B.J., Buckley M.M. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988, 25(2):151-153.
28. Svae T.E., Neisser-Svae A., Bailey A., Reichl H., Biesert L., Schmidt T., et al. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Transfus Apher Sci 2008, 39(1):59-67.
29. Vaara I., Nilsson C.D. [SD plasma safer than fresh-frozen plasma. Comparative studies show advantages of industrially produced plasma]. Lakartidningen 2010, 107(3):106-107.
30. Domen R.E., Hoeltge G.A. Allergic transfusion reactions. Arch Pathol Lab Med 2003, 127(3):316-320.
31. Reutter J.C., Sanders K.F., Brecher M.E., Jones H.G., Bandarenko N. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001, 16(3):134-138.
32. Paul-Ehrlich-Institut Hamovigilanzdaten von 1997 bis 2008 http://www.pei.de/hv-bericht.
33. Funk M.B., Guenay S., Lohmann A., Henseler O., Heiden M., Hanschmann K.M.O., et al. Benefit of transfusion-related acute lung injury risk-minimization measures ΓÇÔ German haemovigilance data (2006ΓÇÔ2010). Vox Sang 2011.
34. Kleinman S., Cameron C., Custer B., Busch M., Katz L., Kralj B., et al. Modeling the risk of an emerging pathogen entering the Canadian blood supply. Transfusion 2010, 50(12):2592-2606.
35. Angus D.C., Musthafa A.A., Clermont G., Griffin M.F., Linde-Zwirble W.T., Dremsizov T.T., et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 163(6):1389-1394.
36. Riedler G.F., Haycox A.R., Duggan A.K., Dakin H.A. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003, 85(2):88-95.
37. Cooke C.R., Kahn J.M., Watkins T.R., Hudson L.D., Rubenfeld G.D. Cost-effectiveness of implementing low-tidal volume ventilation in patients with acute lung injury. Chest 2009, 136:79-88.
38. Bauch C.T., Anonychuk A.M., Pham B.Z., Gilca V., Duval B., Krahn M.D. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007, 25(51):8536-8548.
39. Centers for Disease Control and Prevention Hepatitis A. Epidemiology and prevention of vaccine-preventable diseases (pink book) 2013, http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepa.pdf.
40. Eckman M.H., Kaiser T.E., Sherman K.E. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis 2011, 52(11):1294-1306.
41. Levy A.R., Kowdley K.V., Iloeje U., Tafesse E., Mukherjee J., Gish R., et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008, 11(3):527-538.
42. Liu S., Cipriano L.E., Holodniy M., Goldhaber-Fiebert J.D. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS ONE 2013, 8(3):e58975.
43. Chong C.A., Gulamhussein A., Heathcote E.J., Lilly L., Sherman M., Naglie G., et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003, 98(3):630-638.
44. Wong J.B., Bennett W.G., Koff R.S., Pauker S.G. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998, 280(24):2088-2093.
45. Salomon J.A., Weinstein M.C., Hammitt J.K., Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. J Am Med Assoc 2003, 290(2):228-237.
46. Simpson K.N., Roberts G., Hicks C.B., Finnern H.W. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials 2008, 9(4):225-237.
47. Gebo K.A., Fleishman J.A., Conviser R., Hellinger J., Hellinger F.J., Josephs J.S., et al. Contemporary costs of HIV healthcare in the HAART era. AIDS 2010, 24(17):2705-2715.
48. Centers for Disease Control and Prevention Parvovirus B19 and Fifth Disease http://www.cdc.gov/parvovirusB19/fifth-disease.html#prevention.
49. Annual Change in Medicaid Hospice Payment Rates September 7. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Hospice/Downloads/hospicerates2013.pdf.
50. Kacker S., Ness P.M., Savage W.J., Frick K.D., McCullough J., King K.E., et al. The cost-effectiveness of platelet additive solution to prevent allergic transfusion reactions. Transfusion 2013.
51. Hall M.J. NCHS data brief - inpatient care for septicemia or sepsis: a challenge for patients and hospitals http://www.cdc.gov/nchs/data/databriefs/db62.pdf.
52. Center for Disease Prevention and Control - West Nile Virus Treatment and Symptoms http://www.cdc.gov/westnile/symptoms/.
53. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999, 39(5):479-487.